@conference{04294e0085074316a83347bd25570354,
title = "Persistent reductions in OCS use in patients with severe, OCS dependent asthma treated with dupilumab: LIBERTY ASTHMA TRAVERSE study ",
author = "Mark Gurnell and Christian Domingo and Rabe, {Klaus F} and Andrew Menzies-Gow and David Price and Guy Brusselle and Wechsler, {Michael E} and Changming Xia and Michel Djandji and Rebecca Gall and Jacob-Nara, {Juby A.} and Rowe, {Paul J.} and Yamo Deniz and Shahid Siddiqui",
note = "Acknowledgments and funding sources Data first presented at the American Thoracic Society - 118th International Conference (ATS 2022); San Francisco, CA, USA, May 13-18, 2022. Research sponsored by Sanofi and Regeneron Pharmaceuticals, Inc. ClinicalTrials.gov Identifiers: NCT02528214 (VENTURE)/NCT02134028 (TRAVERSE). Medical writing/editorial assistance was provided by Anthony Aggidis, PhD, of Excerpta Medica, and was funded by Sanofi and Regeneron Pharmaceuticals, Inc., according to the Good Publication Practice guideline.; World Allergy Congress 2022, WAC 2022 Istanbul ; Conference date: 13-10-2022 Through 15-10-2022",
year = "2022",
month = aug,
day = "8",
language = "English",
url = "https://wacistanbul.com/",
}